These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 9848883

  • 1. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
    Burnett JR, Barrett PH, Vicini P, Miller DB, Telford DE, Kleinstiver SJ, Huff MW.
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1906-14. PubMed ID: 9848883
    [Abstract] [Full Text] [Related]

  • 2. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
    Burnett JR, Telford DE, Barrett PH, Huff MW.
    Biochim Biophys Acta; 2005 Dec 30; 1738(1-3):10-8. PubMed ID: 16427354
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
    Parhofer KG, Barrett PH, Schwandt P.
    J Clin Endocrinol Metab; 2000 Nov 30; 85(11):4224-30. PubMed ID: 11095458
    [Abstract] [Full Text] [Related]

  • 6. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
    Wilcox LJ, Barrett PH, Huff MW.
    J Lipid Res; 1999 Jun 30; 40(6):1078-89. PubMed ID: 10357840
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
    Telford DE, Edwards JY, Lipson SM, Sutherland B, Barrett PH, Burnett JR, Krul ES, Keller BT, Huff MW.
    J Lipid Res; 2003 May 30; 44(5):943-52. PubMed ID: 12562847
    [Abstract] [Full Text] [Related]

  • 8. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug 30; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.
    J Clin Endocrinol Metab; 2002 May 30; 87(5):2283-9. PubMed ID: 11994377
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR, Newton RS.
    Atherosclerosis; 1995 Oct 30; 117(2):237-44. PubMed ID: 8801869
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
    Boquist S, Karpe F, Danell-Toverud K, Hamsten A.
    Atherosclerosis; 2002 May 30; 162(1):163-70. PubMed ID: 11947910
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
    Guerin M, Egger P, Le Goff W, Soudant C, Dupuis R, Chapman MJ.
    J Clin Endocrinol Metab; 2002 Nov 30; 87(11):4991-5000. PubMed ID: 12414863
    [Abstract] [Full Text] [Related]

  • 18. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
    Bisgaier CL, Essenburg AD, Auerbach BJ, Pape ME, Sekerke CS, Gee A, Wölle S, Newton RS.
    J Lipid Res; 1997 Dec 30; 38(12):2502-15. PubMed ID: 9458274
    [Abstract] [Full Text] [Related]

  • 19. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb 30; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.